Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug

Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso. The post Bayer Asset Gives Roivant Sciences’ New ‘Vant’…

Read More

There is Still a Significant Need for Community Pharmacies

Losing these retail medication outlets creates more than just pharmacy deserts. In many low-income and underserved areas, drugstores also serve as grocery stores and hubs for essential services, and hence their closures mean communities lose crucial access points for a variety of goods and services. The post There is Still a Significant Need for Community…

Read More